AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01695109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl, 0.2 ml
Study NCT00704795 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
Study NCT00704795 — intervention group
Intervention type: OTHER
Intervention: Isoglycemic iv glucose infusion
Description: The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
Study NCT00524758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen (oculusgen) collagen matrix
Description: Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
Study NCT00524758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC in Trabeculectomy
Description: MMC in Trabeculectomy
Study NCT01837121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the SMS reminder message
Description: the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
Study NCT02266888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan®)
Description: 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
Study NCT02266888 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
Study NCT02859571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02859571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01926457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Prediabetes
Description: Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing
Study NCT01926457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Prediabetes
Description: Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing
Study NCT02132988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-822/OPT-821
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin
Study NCT03363815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Vitamin K
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin
Study NCT03363815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib
Study NCT03718286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
Study NCT03718286 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
Study NCT03834428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Description: A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
Study NCT03834428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICOUGH protocol
Description: Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
Study NCT03834428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICOUGH protocol
Description: Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
Study NCT01808300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B
Study NCT04126941 — intervention group
Intervention type: OTHER
Intervention: Serum calcium concentrations results
Description: To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
Study NCT00972062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bach's Rescue Remedy Cream
Description: 0.5 ml of cream applied to skin site reactions as needed
Study NCT00972062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream 0.5 ml two times a day as needed
Study NCT03841604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate
Description: 50 mg, 100 mg
Study NCT03841604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide methanesulfonate matching placebo
Description: 50 mg, 100 mg
Study NCT01635439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propess
Description: The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
Study NCT01635439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin E2
Description: 3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
Study NCT03247946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: upright head position
Description: Bottle feeding of infants with their head in upward and not supine head position
Study NCT03689621 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Study NCT03689621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Study NCT03868657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
Study NCT03868657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03153943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIP Mobile e-Monitoring support
Description: 3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
Study NCT03153943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workbook support
Description: Printed material support
Study NCT01129856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate ophthalmic solution
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
Study NCT01129856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium citrate buffer solution
Description: Sodium citrate buffer solution 100 mM
Study NCT01337960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Robot Training (SRT)
Description: Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
Study NCT01337960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Locomotor-based Training (TMR)
Description: Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
Study NCT01337960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Only (TMO)
Description: Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
Study NCT00384670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue Vaccine Formulation 17
Description: Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
Study NCT00384670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed Japanese Encephalitis (JE) Vaccine
Description: Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
Study NCT03452657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
Study NCT03452657 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No drug
Description: Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
Study NCT02809482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eucaloric feeding
Description: 3 days of a diet designed to maintain energy balance
Study NCT02809482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Overfeeding
Description: 3 days of a diet designed to induce a 40% positive energy balance
Study NCT03040336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
Study NCT01747876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 is a small molecule inhibitor of CDK4/6.
Study NCT04380285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom heel pads and modified soft molded orthotics
Study NCT04380285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom hard orthotic
Study NCT04226755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 1 gram tid (with every meal)
Study NCT04226755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: 1 gram tid (with every meal)
Study NCT06223984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pulse steroid and nanogam
Description: patients received pulse steroid and ivig treatments in addition to standard treatment.
Study NCT00779155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Resonator
Description: active magnetic field therapy
Study NCT00779155 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Resonator control
Description: inactive magnetic field therapy with placebo fields
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for Infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Study NCT03387085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cis-diamminedichloroplatinum(II)
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03387085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT03387085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT01885741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPBS
Study NCT01737437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: group C
Description: 0.9% normal saline was applied to trachea and laryngoscope blade
Study NCT01737437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group L
Description: 10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
Study NCT01737437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group V
Description: 0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
Study NCT01737437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group LV
Description: 10% Lidocaine was applied on laryngoscope blade and trachea.
Study NCT03762317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
Study NCT03762317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
Study NCT00735436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gliadel/Avastin/CPT-11
Study NCT01342211 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo monthly during treatment phase.
Study NCT01342211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study NCT01342211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Intravenous 10mg/mL based on weight monthly during treatment phase.
Study NCT01342211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study NCT01342211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study NCT04324411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus and ATRA
Description: sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
Study NCT01977989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Powder
Description: For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
Study NCT00118417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Participants will receive clonazepam.
Study NCT00118417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Participants will receive sertraline.
Study NCT00118417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants will receive cognitive behavioral therapy
Study NCT00400166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Mentor
Description: Provided Recovery Mentor services
Study NCT04112719 — intervention group
Intervention type: OTHER
Intervention: supine position
Description: The patient will be placed in a supine position. Changes in cardiac output will be measured.
Study NCT04112719 — intervention group
Intervention type: OTHER
Intervention: 15 degrees lateral tilt
Description: The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
Study NCT04112719 — intervention group
Intervention type: OTHER
Intervention: 30 degrees lateral tilt
Description: The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
Study NCT02206633 — intervention group
Intervention type: DEVICE
Intervention: Hydration Monitor
Description: Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
Study NCT02453321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Block
Description: A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
Study NCT02453321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Block
Description: A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty